Trastuzumab deruxtecan versus trastuzumab emtansine for human epidermal growth factor receptor 2 positive metastatic breast cancer: cost-effectiveness analysis from Iranian experience

Table 2 Base-case cost-effectiveness analysis of T-DM1 and T-DXd for second-line HER2-positive MBC treatment

Strategy	Cost	Incremental cost	Effectiveness	Incremental effectiveness	ICER	NMB
T-DM1	258,039	3,276	1.890	1.700	1,927	-253,476
T-DXd	261,315	3,276	3.591	1.700	1,927	-252,648

T-DM1 Trastuzumab emtansine, T-DXd Trastuzumab deruxtecan, ICER Incremental Cost Effectiveness Ratio, NMB Net Monetary Benefit

ISSN: 1472-6963